August 24, 2017
Karo Pharma to buy Weifa for €138M
Karo Pharma will launch voluntary cash offer to acquire the entire issued share capital of Weifa for € 3.78 per share in cash.
Pharmaceuticals, Biotechnology and Life Sciences
Karo Pharma will launch voluntary cash offer to acquire the entire issued share capital of Weifa for € 3.78 per share in cash.
Weifa has made a deal with New Zealand’s AFT Pharmaceuticals according to which it will sell drugs for pain relief and fever symptoms in the Nordic region (Norway, Sweden, Denmark, Finland and Iceland).